Literature DB >> 21676472

Oral administration of bovine lactoferrin upregulates neutrophil functions in a dog with familial β2-integrin-related neutrophil dysfunction.

Saori Kobayashi1, Yuya Abe, Osamu Inanami, Shinichi Oda, Koji Yamauchi, Careen Hankanga, Jun Yasuda, Reeko Sato.   

Abstract

Lactoferrin, a glycoprotein present in neutrophils and exocrine secretions, plays important roles in host defense. Administration of bovine lactoferrin has been reported to modulate various neutrophil functions. We found a mixed-breed male dog with novel familial neutrophil dysfunction. The disorder was caused by a decrease of β2-integrin expression encoding CD18 without mutation. Antibiotics therapy alone did not influence a series of neutrophil functions in the same dog. We examined the effects of oral administration of bovine lactoferrin on the neutrophil function and clinical symptoms in the same dog. Oral chronic administration of bovine lactoferrin increased neutrophilic β2-integrin gene expression comparable to normal dogs, followed by the upregulation of surface CD18 expression. Concurrently, the superoxide production, phagocytic activity and adherence that were β2-integrin-related neutrophil functions increased to normal canine levels. The chronic inflammation from bacterial upper respiratory infections and pneumonia was also alleviated in the dog. Our results indicate that oral treatment with bovine lactoferrin increases neutrophil β2-integrin transcript level, leading to the upregulation of neutrophil functions and improvement of clinical symptoms in the dog with familial neutrophil dysfunction.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676472     DOI: 10.1016/j.vetimm.2011.05.027

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  1 in total

1.  A 17-kDa Fragment of Lactoferrin Associates With the Termination of Inflammation and Peptides Within Promote Resolution.

Authors:  Aviv Lutaty; Soaad Soboh; Sagie Schif-Zuck; Orly Zeituni-Timor; Ran Rostoker; Malgorzata J Podolska; Christine Schauer; Martin Herrmann; Luis E Muñoz; Amiram Ariel
Journal:  Front Immunol       Date:  2018-03-28       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.